Limiting Medicaid Access To Accelerated Approval Drugs: Costs And Consequences Comment
The American journal of managed care（2021）
摘要
Accelerated approval drugs account for less than 1% of Medicaid spending, but states seek CMS approval to avoid coverage of these drugs and cut costs.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要